GENERAL16 Sept 2026
Kopran soars 10%, rallies 154% in FY27 so far; what's driving pharma stock?
Kopran, an Indian pharma company with integrated formulations and active pharmaceutical ingredients (APIs) operations, jumped 10 per cent in a session and has rallied 154 per cent so far in FY27. Average volumes more than doubled, with 13.12 million shares traded across BSE and NSE combined. For anyone tracking or holding the stock, such sharp moves often come with equally sharp swings.
Key Statutory Highlights
- Kopran shares rose 10 per cent in a single session and have gained 154 per cent so far in FY27.
- Average volumes on the counter more than doubled, with a combined 13.12 million shares traded on BSE and NSE.
- Kopran is an Indian pharmaceutical company with integrated operations across formulations and Active Pharmaceutical Ingredients (APIs).
Actionable Advice for Taxpayers / Founders:Treat this as news, not a tip. If you are planning to buy, sell or hold, look at the company's latest financials and your own risk comfort first, and check with a registered investment adviser before you act.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: